(turmeric), and have received much attention due to their pleiotropic anticancer properties. Recent evidence suggests that curcumin and analogs prevent the activation of a variety of signaling pathways, including the MAPK, PI3K/Akt, and NF-kB pathways, resulting in the induction of apoptosis, prevention of proliferation, and suppression. In addition to these processes, curcumin has been shown to enhance the efficacy of the conventional anti-cancer modalities such as radiation and chemotherapy. By suppressing the expression of matrix metalloproteinases (MMPs), which are enzymes that break down the extracellular matrix and promote cancer cell invasion and metastasis, curcumin also demonstrates anti-metastatic qualities. Inflammation and the advancement of cancer are linked to the NF-κB signaling pathways, which are also suppressed by curcuminoids. Along with these processes, curcumin has demonstrated the ability to improve the effectiveness of traditional cancer treatments, including radiation and chemotherapy. It increases the sensitivity of cancer cells to various therapies, which enhances the therapeutic results. However, curcumin's low bioavailability limits its therapeutic use. Its anticancer potency may be increased, and this restriction may be overcome due to recent developments in drug delivery technologies, such as curcumin-loaded nanoparticles. Since they can target several different molecular pathways and improve the effectiveness of current treatments, curcuminoids are a promising family of chemicals for the prevention and treatment of cancer.
Globally, environmental pollution caused by resilient protein like collagen is escalating due to inefficient disposal practices. Accumulation of collagen waste poses ecological threat, necessitating management strategies. Current study discloses collagenolytic bacterium, Bacillus siamensis strain Z1, isolated from marine water (Goa) demonstrating collagen breakdown and inducing collagenase biosynthesis. Production kinetics revealed optimal collagenase production (4.55 U/mL) on 2nd day with a protein content of 0.69 mg/mL. Influence of physiochemical parameters, including inoculum size, metal ions, carbon and nitrogen sources, pH and temperature on collagenase yield was optimized achieving 17.93 folds enhancement by central composite design. Silver (AgNP) and Zinc oxide (ZnONP) nanoparticles were biosynthesized using collagen hydrolysate derived from marine collagen through collagenase action and characterized using UV-Visible spectroscopy, Fourier Transform Infrared Spectroscopy, X-ray Diffraction, Scanning Electron Microscopy with Energy Dispersive X-ray, Thermogravimetric Analysis and Atomic Force Microscopy elucidated thermostability, structure and surface characteristics. Antibacterial effect of nanoparticles was observed against B. cereus and E. coli. AgNP and ZnONP demonstrated antioxidant properties assessed by ABTS and DPPH assays. AgNP and ZnONP exhibited cytotoxicity on MCF-7 breast cancer cell lines, with IC50 values 8.87 µg/mL and 25.21 µg/mL respectively. The study highlights biotechnological potential of collagenase in generating bioactive products for therapeutical and biomedical advancements.
= 1.79 ± 0.05 µM), supporting its targeted anti-angiogenic mechanism. Flow cytometry analysis showed that 7e induced G0/G1 cell cycle arrest and markedly increased apoptotic cell populations. This was further confirmed by upregulation of Bax, Caspase-3, and Caspase-8, alongside downregulation of Bcl-2, indicating activation of both intrinsic and extrinsic apoptotic pathways. Interestingly, 7e inhibited cancer cell migration, suggesting a potential anti-angiogenetic effect. Density functional theory (DFT) calculations revealed that 7e possesses a conjugated electronic system with a suitable frontier orbital distribution, moderate HOMO-LUMO gap, and a favorable electrostatic potential for receptor interaction. Molecular docking and dynamics simulations demonstrated stable binding of 7e within the VEGFR-2 active site, supported by consistent RMSD, hydrogen bonding, and compact structural behavior. MM-GBSA calculations confirmed favorable binding free energy, while per-residue decomposition and protein-ligand interaction fingerprint analysis identified key stabilizing interactions. Essential dynamics and free energy landscape mapping further confirmed a stable and energetically favorable conformational state. ADMET and toxicity predictions indicated acceptable pharmacokinetic properties, low mutagenic risk, and an overall favorable safety profile. Collectively, these findings identify compound 7e as a promising VEGFR-2-targeted anticancer lead with strong enzymatic inhibition, potent cytotoxicity, and a well-supported mechanistic profile integrating experimental and computational evidence.
Aims This study aimed to design, synthesize, and evaluate novel benzanilide derivatives as potential anticancer agents targeting VEGFR-2-mediated tumor angiogenesis.Materials and methods Eight benzanilide derivatives (7a-e, 9a-b, and 11) were synthesized and structurally confirmed using spectroscopic methods. The compounds were evaluated via molecular docking, in silico ADMET profiling, in vitro cytotoxicity against MCF-7, MDA-MB-231, HepG-2, and HCT-116 cancer cell lines, and selectivity assessment using WI-38 and WISH normal cell lines. VEGFR-2 enzyme inhibition was also determined for the most active compound.Results Compound 11 exhibited the highest cytotoxic activity with IC50 values of 6.08, 5.76, 7.94, and 4.64 µM against MCF-7, MDA-MB-231, HepG-2, and HCT-116, respectively, comparable to sorafenib. It showed potent VEGFR-2 inhibition (IC50 = 0.414 µM) superior to sorafenib (0.809 µM). Mechanistic studies indicated activation of apoptosis via upregulation of Bax, Caspase-3, and Caspase-8 and downregulation of Bcl-2. ADMET results revealed favorable pharmacokinetic properties and acceptable safety profiles.Conclusions Compound 11 represents a promising VEGFR-2 inhibitor with potent anticancer activity and favorable drug-like properties, warranting further optimization and development.
Archiv der Pharmazie · مجلد 359 (9) · e70328-e70328
ABSTRACT A new series of chromene derivatives ( 12–19 ) was rationally designed as potential inhibitors of vascular endothelial growth factor receptor‐2 (VEGFR‐2) by integrating essential pharmacophoric and structural features. The target compounds were synthesized and structurally confirmed using spectroscopic techniques. Their in vitro antiproliferative activities were evaluated against a panel of human cancer cell lines (MCF‐7, MDA‐MB‐231, HepG‐2, and HCT‐116) alongside normal human cells (WI‐38 and WISH), in addition to a VEGFR‐2 enzyme inhibition assay. Among the synthesized derivatives, compound 17 emerged as the most potent candidate, displaying low micromolar IC 50 values across all tested cancer cell lines and superior VEGFR‐2 inhibitory activity (IC 50 = 0.518 µM) compared with the reference drug sorafenib (IC 50 = 0.809 µM). Mechanistic investigations revealed that compound 17 induced pronounced cell cycle arrest and triggered apoptosis, as demonstrated by Annexin V–FITC/PI flow cytometric analysis. Computationally, Density Functional Theory (DFT) calculations demonstrated favorable electronic properties for compound 17, supporting effective ligand–receptor interactions. Molecular docking and 100‐ns molecular dynamics (MD) simulations, complemented by MM‐GBSA binding free energy calculations, Protein–Ligand Interaction Fingerprinting (Pro‐LIF), Principal Component Analysis (PCA‐T), and Free Energy Landscape (FEL) analyses, confirmed the stability and favorable binding energetics of compound 17 within the VEGFR‐2 active site. Furthermore, in silico ADME–Tox profiling predicted acceptable pharmacokinetic behavior and a favorable safety profile. Collectively, these experimental and computational findings identify compound 17 as a promising and mechanistically well‐characterized VEGFR‐2 inhibitor, warranting further in vivo investigation.
Journal of Computational Biophysics and Chemistry · 1-20
The development of selective vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors remains a promising strategy for anticancer therapy targeting tumor angiogenesis. In the study at hand, a novel benzanilide-based derivative, ACEB-Cl, was rationally designed by assimilating fundamental pharmacophoric characteristics essential for VEGFR-2 inhibition. ACEB-Cl was evaluated using a comprehensive approach that combined computational modeling, synthesis, and in vitro biological assessment. Density functional theory (DFT) calculations revealed a favorable electronic profile, with distinct nucleophilic and electrophilic regions that could support potential interactions within the VEGFR-2 binding pocket. Docking and molecular dynamics (MD) simulations suggested stable binding of ACEB-Cl within the ATP-binding pocket, supported by strong hydrophobic interactions and favorable binding free energy ([Formula: see text] kcal/mol). Following synthesis, ACEB-Cl confirmed potent anti-VEGFR-2 activity in an ELISA-based assay (IC[Formula: see text]M), showing higher potency than sorafenib. Western blot analysis further confirmed significant downregulation of phosphorylated VEGFR-2 in MDA-MB-231 cells. In vitro cytotoxicity studies revealed selective anticancer activity, with reduced toxicity toward normal Vero cells and favorable selectivity indices. Mechanistically, ACEB-Cl triggered G0/G1 phase arrest and significantly increased apoptotic cell death, highlighting its ability to suppress cancer cell proliferation. Additionally, ADMET and toxicity estimations indicated a balanced pharmacokinetic and safety profile, with improved solubility, acceptable absorption, and reduced toxicity risks compared to sorafenib. Overall, this integrated study pinpointed ACEB-Cl as a promising VEGFR-2-targeted anticancer lead compound with strong inhibitory potency and a clearly defined mechanism of action, supporting its progression for further improvement.
VEGFR-2 inhibitorsbenzanilidestumor angiogenesisanticancer drug discovery
Journal of Computational Biophysics and Chemistry · 1-20
The pursuit of selective vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors continues to be a key approach in anticancer drug discovery. In this context, a new benzanilide-based derivative, Z-CMPBC, was designed following essential VEGFR-2 pharmacophoric requirements and investigated through combined computational and biological approaches. Density functional theory (DFT) calculations at the B3LYP/6-31[Formula: see text]G(d, p) level indicated favorable electronic characteristics, including balanced chemical hardness and pronounced electrophilicity, suggesting a strong propensity for interaction within kinase active sites. Molecular docking, supported by 200 ns molecular dynamics simulations, demonstrated stable accommodation of the compound within the VEGFR-2 binding pocket. Binding free energy calculations using the MM-GBSA method revealed a significant interaction profile ([Formula: see text] kcal/mol), mainly governed by van der Waals forces and persistent hydrophobic interactions with critical residues. Biological assessment confirmed potent VEGFR-2 inhibition, with an IC[Formula: see text] value of [Formula: see text]M, closely comparable to sorafenib ([Formula: see text]M). Western blot analysis further verified a reduction in phosphorylated VEGFR-2 (pY1054/Y1059) levels in MCF-7 cells, supporting effective intracellular kinase inhibition. Additionally, Z-CMPBC exhibited pronounced cytotoxicity, particularly against MCF-7 breast cancer cells (IC[Formula: see text]M), along with a high selectivity index ([Formula: see text]) relative to normal Vero cells. Flow cytometry analysis demonstrated induction of G0/G1 phase arrest, accompanied by enhanced apoptotic activity (34.05%) compared to untreated cells. In silico ADMET and toxicity predictions suggested acceptable pharmacokinetic behavior and safety characteristics. Overall, these findings highlight Z-CMPBC as a promising VEGFR-2 inhibitor with potential for further development as an anticancer agent.
VEGFR-2 inhibitorsanticancer drug discoverykinase inhibitorsMCF-7 cells
Journal of King Saud University - Science · مجلد 38 · 3852025-3852025
Lung cancer is the leading cause of cancer-related death in numerous countries worldwide. Given their severe side effects that can impact the patients’ quality of life, the current treatment approaches need more specific targeting to reduce chemotherapeutic toxicities. Cell-based targeted delivery has recently gained momentum as a promising platform for the delivery of anticancer drugs. As a new biotechnology platform, bacterial ghosts (BGs) have novel biomedical applications, including targeted drug delivery systems. In the current work, the BG of Streptococcus pneumoniae and Klebsiella pneumoniae ghosts were used as potential targeted-delivery agents for treating lung cancer cells. Bacterial ghosts of S. pneumoniae and K. pneumoniae were prepared using the most recent protocol (tween/acid). The doxorubicin (DOX) uploading was optimized by applying the required conditions to maximize loading capacity. We evaluated the DOX-loaded BGs’ antiproliferative and apoptotic effects on two lung cancer cell lines (H69A, A549) and one normal human embryonic kidney cell line (HEK293) in comparison to free BGs and DOX alone. We also tested the sustained release patterns for each formula. We predicted the mechanism of augmenting the actions of both systems by a protein-protein docking study. The preparation of well-formulated ghosts of both bacteria was successful and confirmed. The loading capacity was maximized to 31.2 ± 3.1% (n=3) for S. pneumoniae ghosts (SPG) and 28.8± 2.6% (n=3) for K. pneumoniae ghosts (KPG). The sustained release pattern of both SPG and KPG followed the Higuchi kinetic model, while Free DOX exhibited a rapid release pattern consistent with the first-order kinetic model. The antiproliferative activity using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay revealed the superiority of SPG loaded with DOX (SPG-DOX) over all other tested formulae (10.8% viability) on multi-drug-resistant lung cancer cells (H69A). The IC50s of SPG-Dox loaded were one-sixth and one-fifth of the IC50 of the Free DOX in H69A and A549, respectively, indicating more potency. The cell viability was 46.6% upon using Free DOX. In non-small cell lung cancer cells (A549), the SPG-DOX formula also showed superior antiproliferative activity (23.1% viability), as compared to control vehicles. SPG and KPG showed the highest safety toward the normal cell lines (HEK293), with more than 80% of cells surviving. Using H69A cells, KPG-DOX showed superior apoptotic activity (58.2%) over Free DOX, which achieved less than 20% cellular apoptosis. In A549 cells, SPG-DOX showed apoptotic activity of 57.7% compared to Free DOX. (32.5%). The docking study showed a strong binding interaction between a KPG surface protein (4HWM) and the overexpressed non-small cell lung cancer carcinoma receptor, epidermal growth factor receptor kinase domain (EGFR 2ITO), with a binding score (S) for the interaction of -63.94 kcal/mol. The interaction was -61.26 of SPG surface protein (3ZPP) with EGFR. The application of S. pneumoniae and K. pneumoniae BGs loaded with DOX represents a promising targeted drug delivery system for the treatment of lung cancer. The superior potency and safety of both systems warrant further investigation into their preclinical and clinical activities.
The continuous progression of cancerous severity due to the interaction of physical (ultraviolet radiation), chemical (smoking, mycotoxins, and heavy metals), and biological (microbial populations) carcinogens inspired scientists to develop a correlation between active therapeutic agents and cancer proliferation. This review highlights the molecular mechanism by which lycopene imparts its anticancerous role, focusing on clinical and animal trials to validate its effectiveness. The antioxidant profile of lycopene promotes anticancerous properties that reduce cancer prevalence by activating cell signaling pathways and gene expression (involved in cancer cell proliferation). Lycopene's anti-inflammatory properties suppresses the tumor growth and development-promoting pathways, such as the PI3K/Akt/mTOR pathway. The anticancer property of lycopene is also evidenced by its inhibitory potential of the Wnt/β-catenin signaling pathway that is involved in cancer cell modulation and propagation. Lycopene also suppresses and neutralizes oxidative stress and reactive oxygen species (ROS)-induced DNA damage, preventing gene mutation. Inflammation-induced cell death is mitigated by lycopene's anti-inflammatory potential that lowers the expression of interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Several clinical and randomized control trials have revealed the effect of lycopene supplementation in the management of cancer, including breast cancer, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, skin cancer, oral cancer, liver cancer, gastric cancer, and kidney cancer, by lessening prostate-specific antigen (PSA) levels. These studies also accentuate certain limitations that need further trials to evaluate the long-term consequences of lycopene supplementations and their specific effective dose.
Punicalagin, being a bioactive polyphenol, has gained significant interest owing to its potential anticancer effects. Researchers are studying punicalagin to determine its ability to inhibit cancer cell proliferation. This paper focuses on highlighting the therapeutic potential of punicalagin against tumors and cancers. Punicalagin inhibits tumor growth within the body through various cellular pathway interactions. This compound effectively eliminates tumor cells from the liver, stomach, prostate, and lungs. Different animal model studies have demonstrated the potential of punicalagin in blocking the MAPK/ERK and PI3K/AKT/mTOR signaling pathways, fighting against cancer. Through the inhibition of cell division, punicalagin may be capable of eradicating breast cancer cells. Punicalagin strongly inhibits the activities of vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and uPA. Punicalagin effectively inhibits the androgen receptor (AR), a protein essential for the development and metastasis of prostate cancer. Lung cancer cells can be eliminated by initiating the caspase cascade and inhibiting protein synthesis, which is facilitated by punicalagin. In numerous animal models, punicalagin significantly reduces metastasis. Cyclokinase B1 and cyclin-dependent kinase 2 promote colon cancer; when colon cancer cells reach the G2/M phase, punicalagin induces apoptosis by inhibiting the action of these proteins. Punicalagin inhibits tumor development and cancer propagation by inhibiting blood vessel proliferation. There is still a need for further clinical trials and studies to fully reveal punicalagin's potential as well as its safety; despite the fact that it may decrease the threat of increasing tumors and provide an alternative treatment for many cancers.
Journal of Taibah University for Science · مجلد 19 (1)
A novel exopolysaccharide (EPS-R1) from the Red Sea bacterium Bacillus tequilensis MYG163 was isolated and characterized. The strain produced 6.33 g/l of EPS-R1, which was identified as a sulfated heteropolysaccharide containing uronic acid, N-acetyl glucose amine, and various monosaccharides. EPS-R1 showed strong antioxidant properties (>80% in DPPH and ABTS assays) and anti-inflammatory effects on COX-1 (IC50 = 25.74 µg/mL) and COX-2 (IC50 = 48.57 µg/mL). While safe for normal cells, it demonstrated cytotoxicity against colon (IC50 = 203.25 µg/mL) and pancreatic cancer cells (IC50 = 122.99 µg/mL). The compound effectively inhibited Candida albicans (MIC = 15.62 µg/mL) and showed superior antibacterial activity compared to gentamicin against Enterococcus faecalis (33 mm vs. 30 mm) and Klebsiella pneumoniae (42 mm vs. 17 mm). It significantly reduced bacterial biofilm formation (86-88% inhibition at 75% MBC) and Candida biofilms (60-90% reduction). These diverse bioactivities suggest EPS-R1's potential as a therapeutic agent.
Archiv der Pharmazie · مجلد 358 (7) · e70042-e70042
ABSTRACT A series of thiadiazole‐based derivatives were synthesized and evaluated for their potential as VEGFR‐2 inhibitors and anticancer agents. Among them, compound 7b demonstrated significant cytotoxic activity against MCF‐7 breast cancer cells, with an IC 50 value of 6.13 µM, surpassing that of the reference drug sorafenib (IC 50 : 7.26 µM). Compound 7b also exhibited potent VEGFR‐2 inhibition with an IC 50 of 40.65 nM, outperforming sorafenib (IC 50 : 53.32 nM). Further investigation into the mechanism of action revealed that compound 7b induced significant changes in the cell‐cycle distribution of MCF‐7 cells, causing G1 arrest and delaying progression through the G2/M phase. Apoptosis analysis demonstrated that compound 7b primarily induced late apoptosis (55.90%) and necrosis (21.81%), with only 22.26% of cells remaining viable. Treatment with 7b increased the expression of the proapoptotic gene BAX (4.19 ± 0.34‐fold) and suppressed the expression of the antiapoptotic gene Bcl‐2 (0.38 ± 0.02‐fold), resulting in a dramatic increase in the BAX/Bcl‐2 ratio (11.03 ± 1.66‐fold). Additionally, caspase‐8 and caspase‐9 levels were elevated by 2.99 ± 0.22‐fold and 4.13 ± 0.11‐fold, respectively, confirming activation of both intrinsic and extrinsic apoptotic pathways. In conclusion, compound 7b is a potent VEGFR‐2 inhibitor with promising anticancer activity, demonstrating cytotoxicity, inhibition of cell migration, and induction of apoptosis in MCF‐7 cells. These results suggest that compound 7b has the potential to be developed as a therapeutic agent for breast cancer treatment, warranting further in vivo and mechanistic studies.
thiadiazole derivativesVEGFR-2 inhibitorsanticancer agentsbreast cancer
BACKGROUND: Topoisomerase II (Topo II) remains a validated target for anticancer therapy, with many clinically used agents acting via DNA intercalation and enzyme inhibition. However, their clinical use is limited by severe toxicity and resistance. In this study, we investigate aotaphenazine, a rare hydrophenazine derivative isolated from Streptomyces sp. IFM 11694 as a potential novel Topo II inhibitor with selective anticancer activity. METHODS: Molecular docking and 400 ns molecular dynamics (MD) simulations were employed to evaluate aotaphenazine's binding mode within the DNA-Topo II complex (PDB: 3QX3). MM-GBSA calculations quantified interaction energetics, while ProLIF and PLIP analyses detailed the interaction patterns. Topo II inhibition was assessed via in vitro enzymatic assays. Cytotoxicity (MTT) assays were conducted against a panel of human cancer and normal cell lines. Flow cytometry was used to evaluate apoptosis and cell cycle progression in MDA-MB-231 cells. RESULTS: aotaphenazine demonstrated a docking binding energy of -19.12 kcal/mol and remained stably intercalated within the DNA groove during MD simulations. MM-GBSA analysis showed a total binding free energy of -29.81 kcal/mol, driven primarily by van der Waals forces. Interaction profiling identified consistent π-stacking with Cyt8 and Thy9, and strong binding contributions from Ade12 and Gua13. Enzymatic assays confirmed Topo II inhibition with an IC50 of 45.01 nM, comparable to doxorubicin (30.16 nM). In vitro cytotoxicity analysis revealed moderate activity across cancer cell lines (IC50 = 26.30-54.35 µM) and significantly reduced toxicity in normal WI-38 and WISH cells (IC50 = 69.86 µM and 84.72 µM, respectively). Flow cytometry showed that aotaphenazine induced early (20.98%) and late apoptosis (42.80%), along with S-phase cell cycle arrest (43.99%) and a marked reduction in the G2/M population in MDA-MB-231 cells. CONCLUSION: aotaphenazine exhibits a compelling combination of Topo II inhibition, DNA intercalation, and selective anticancer activity, supported by both computational modeling and biological validation. Its lower cytotoxicity toward normal cells and ability to induce apoptosis and cell cycle arrest suggest strong therapeutic potential. These findings establish aotaphenazine as a promising lead compound for the development of safer and more selective Topo II-targeting anticancer agents.
topoisomerase II inhibitionDNA intercalationanticancer activitynatural product isolation